Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Sjogrens Disease

Tundra lists 4 Sjogrens Disease clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07760818

A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage. The study will assess how efgartigimod PH20 affects symptoms of SjD specifically linked to the peripheral nervous system; the safety and tolerability of efgartigimod PH20; and whether receiving efgartigimod PH20 affects the participant's quality of life.

Gender: All

Ages: 18 Years - Any

Updated: 2026-08-12

Sjogrens Disease
Primary Sjögren's Syndrome Painful Sensory Neuropathies
RECRUITING

NCT06991114

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

Gender: All

Ages: 18 Years - Any

Updated: 2026-07-31

22 states

Refractory Rheumatoid Arthritis (RA)
Idiopathic Inflammatory Myopathies (IIMs)
Systemic Sclerosis (SSc)
+6
RECRUITING

NCT07229144

OM336 in Seropositive Autoimmune Diseases

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-06-15

1 state

Sjogrens Disease
Idiopathic Inflammatory Myopathy (IIM)
ENROLLING BY INVITATION

NCT06583395

Quest to Analyze One Thousand Humans Meditating

This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and clinical populations.

Gender: All

Ages: 21 Years - Any

Updated: 2024-11-01

1 state

Amyotrophic Lateral Sclerosis (ALS)
Angina, Stable
Anxiety
+52